England Reimburses Ultra-Rare Disease Drug Joenja, While EU Regulatory Review Drags On

 
• By Neena Brizmohun
  
Close-up shot of pills with stamped pound sterling GBP symbol on them
NICE believes that Joenja is cost-effective
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Rare Diseases